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Background: The aim of this single-center study is to review the transplant outcomes of patients receiving 
lung transplantation (LTx) using intraoperative extracorporeal membrane oxygenation (ECMO) according to 
the perioperative use of ECMO.
Methods: We retrospectively reviewed the transplant outcomes of 107 consecutive patients who underwent 
LTx using intraoperative ECMO between March 2013 and August 2016 at Severance Hospital of Yonsei 
University (Seoul, Korea). 
Results: Patients were divided into the following three groups according to the use of perioperative 
ECMO: only intraoperative ECMO (n=47) or extended post-operative ECMO but no bridging and no 
postoperative ECMO re-implantation (secondary ECMO; n=28) as Group A (n=75); bridging ECMO 
without secondary ECMO (n=14) as Group B; and secondary ECMO with (n=7) or without (n=11) bridging 
as Group C. Baseline demographics were comparable among the three groups. The mean duration of 
preoperative ECMO bridging was 16.4±15.6 (n=21). After a median of 17.7 months (range, 3.1–40.9 months) 
for survivors, the one year overall survival (OS) rates after LTx for the three groups were 76.3%±5.2% for 
Group A, 59.9%±14.3% for Group B, and 14.0%±9.0% for Group C (P<0.0001). The secondary ECMO 
(Group C) was established a mean of 7.9±5.3 days after LTx. The main cause of secondary ECMO was acute 
respiratory failure from pneumonia, and the main cause of death was infection-related events.
Conclusions: Our data suggests that the use of perioperative ECMO, including its extended postoperative 
use during LTx, is feasible and has favorable outcomes. However, as shown by the poor survival outcome 
after secondary ECMO, the development of solid strategy to reduce the need for secondary ECMO 
implantation after LTx seems important.
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Introduction
Following pivotal progress in technical improvements 
and safety as demonstrated in the CESAR trial (1) and 
other recent encouraging survival data (2), extracorporeal 
membrane oxygenation (ECMO) is now considered in 
a broader spectrum of adult patients with respiratory 
failure, and the feasibility and advantages of its use as a 
bridge to lung transplantation (LTx) have been suggested 
by an increasing number of encouraging findings (3). 
Moreover, there has been a notable paradigm shift from 
intraoperative cardiopulmonary bypass (CPB) to ECMO 
for intraoperative cardiopulmonary support during LTx. 
In line with several theoretical advantages of ECMO 
compared with CPB, including a miniature circuit 
requiring a closed circulation circuit with no cardiotomy 
suction and enhanced biocompatibility leading to lesser 
anticoagulation requirement that potentially lowers the 
activation of the coagulation cascade and inflammatory 
system (4),  increasing data on the comparison of 
intraoperative ECMO with CPB favors the use of ECMO 
(5-9). We have recently reported our experience of the 
transition to routine use of intraoperative venoarterial 
ECMO (vaECMO) from CPB with encouraging results. 
The purpose of this single-center study was to review 
the transplant outcomes of patients receiving LTx using 
intraoperative ECMO according to the perioperative use 
of ECMO.
Methods
Patients
Intraoperative cardiopulmonary support using vaECMO 
has been used routinely for all patients undergoing LTx 
at our institution since March 2013 (10). We conducted 
a retrospective review of clinical data on 107 consecutive 
adult patients (>18 years of age) who underwent LTx 
with intraoperative vaECMO between March 2013 and 
August 2016 at Yonsei University Severance Hospital 
(Seoul, Korea). Pre-, intra-, and post-operative data and 
laboratory and respiratory data were obtained at the 
initiation and during ECMO therapy using a retrospective 
review of the prospectively recorded registry database and 
electronic medical records. This study was approved by the 
Institutional Review Board of Yonsei University Health 
Service at Severance Hospital and complied with the 
Declaration of Helsinki.
Definition
Extended ECMO use was defined if the patient left 
the operative room with a running ECMO system, 
and secondary ECMO use was defined if the patient 
required re-insertion of ECMO after decannulation (5). 
Bridging ECMO use was defined if the patient received a 
bridging therapy with ECMO before LTx. Primary graft 
dysfunction (PGD) was assessed and graded according to 
the International Society for Heart and LTx lung transplant 
injury grades (11), after excluding other potential diagnoses 
as previously reported (12). We considered PGD recorded 
between 48 and 72 hours after LTx for the analysis.
LTx and ECMO technique
The operative technique and general principle for LTx 
have previously been described (10,12). Briefly, the surgical 
approaches were either bilateral anterolateral thoracotomy 
preferably in the fourth intercostal space for single- (n=8) 
and double- (n=99) LTx. All patients received standard 
triple immunosuppressant consisting of calcineurin inhibitor 
(cyclosporine or tacrolimus), mycophenolate mofetil, and 
methylprednisolone. All intraoperative cardiopulmonary 
support was performed via vaECMO, while those who 
were initially on bridging veno-veno ECMO (vvECMO) 
required a change to vvaECMO (veno-veno-arterial 
ECMO). vaECMO was established during anesthesia 
induction or after open-chest or hilar dissection. Following 
a heparin infusion of 2,000 units, patients were cannulated 
peripherally, centrally, or a combination of both. The target 
activated clotting time was 150–180 seconds during ECMO. 
Protamine was used only on weaning from intraoperative 
ECMO. Other institutional procedures regarding ECMO 
techniques were performed as described previously (10). 
Statistical analysis
Continuous variables were compared using the Kruskal-
Wallis test and shown as the median with interquartile 
range (IQR). Categorical data were analyzed using Fisher’s 
exact test or Pearson’s χ2 test, depending on the distribution, 
and these data are shown as absolute frequencies and 
percentages. The overall survival (OS) curve after LTx was 
plotted using the Kaplan-Meier method, and differences 
were compared using the log-rank test. All statistical 
analyses were performed using Statistical Package for the 
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Social Sciences version 16.0 software (SPSS Inc., Chicago, 
IL, USA).
Results
Patient demographics 
During the study period, a total of 107 adult patients 
(median age 55 years, range, 18–75 years; male sex, 
n=64) were transplanted using ECMO for intraoperative 
cardiopulmonary support. Indications for LTx were 
idiopathic pulmonary fibrosis (IPF; n=62), connective tissue 
disease ILD (n=9), COPD (n=6), bronchiectasis (n=5), 
bronchiolitis obliterans syndrome after allogeneic stem cell 
transplantation (n=12), acute interstitial pneumonitis (n=4), 
pulmonary hypertension (n=3), lymphangioleiomyomatosis 
(n=3) and other indications (n=3).
Perioperative use of ECMO support
The patient population was grouped as summarized 
in Figure 1. Of 107 patients undergoing LTx using an 
intraoperative ECMO, 60 (56.1%) patients received 
additional ECMO support. That is, 21 of these 60 patients 
(35%) were on ECMO for a bridging therapy before 
transplant and 18 patients (30.0%) required a secondary 
use of ECMO support after decannulation; whereas, in 
55 of the patients (91.7%), ECMO support was extended 
into the postoperative period with a configuration change 
from vvaECMO to vvECMO. The remaining 47 patients 
received ECMO support only intraoperatively (43.9%) and 
were weaned off from ECMO in operation room.
Survival according to the perioperative use of ECMO 
support
We first analyzed the OS according to the perioperative 
uses of ECMO, arbitrary divided into five clinical situations: 
(I) 47 (43.9%) patients receiving only intraoperative ECMO 
use; (II) 28 (26.2%) patients with extended use of ECMO 
but without bridging ECMO nor second ECMO; (III) 14 
(13.1%) patients receiving bridging ECMO with (n=13) 
or without (n=1) extended ECMO but not requiring a 
second ECMO; (IV) 11 (10.3%) patients receiving a second 
ECMO with (n=7) or without (n=4) extended ECMO but 
no bridging ECMO; (V) 7 (6.5%) patients with bridging 
and secondary ECMO (all required extended use). After 
observing the OS of each group [1 year OS, group (I): 
77.8%±6.6%; group (II): 73.8%±8.5%; (III): 60.0%±14.3%; 
(IV): 25.5%±15.1%; (V): 0%] as shown in Figure 2A, we 
merged the patients into three arbitrary groups: Group 
A (n=75, 70.1%), patients receiving only intraoperative 
ECMO or extended ECMO but no bridging nor second 
ECMO [(I) + (II)]; Group B (n=14, 13.1%), patients 
Lung transplantation 
using intraoperative VA-ECMO 
(n=107)
Only intra-operative ECMO 
without bridging, extended, or secondary 
ECMO use
(n=47)
Bridging ECMO
(n=21)
No secondary ECMO
(n=14)
 - ECMO extension, n=13
 - No ECMO extension, n=1
No secondary ECMO
(n=28)
 - ECMO extension, n=28
Intra-operative ECMO 
with bridging, extended, and/or secondary 
ECMO use
(n=60)
No bridging ECMO
(n=39)
Secondary ECMO
(n=7)
 - ECMO extension, n=7
Secondary ECMO
(n=11)
 - ECMO extension, n=7
 - No ECMO extension, n=4
Figure 1 Patient subgroups according to the perioperative use of ECMO for lung transplantation. ECMO, extracorporeal membrane oxygenation.
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receiving bridging ECMO but no second ECMO (III); and 
Group C (n=18, 16.8%), patients receiving a second ECMO 
with (n=7) or without (n=11) a bridging ECMO [(IV) + (V)].
Comparisons of clinical characteristics and transplant 
outcomes in Group A, B, and C
Baseline demographics of patients and donors were 
similar among the three groups, as summarized in Table 1. 
Patients who required re-implantation of secondary ECMO 
after LTx (Group C) showed male predominance and 
higher body mass index, while patients in Group A, who did 
not receive bridging ECMO nor secondary ECMO, had 
donors with higher PaO2 values compared to Groups B and 
C. The waiting time was longer in Group A, as compared 
with Groups B and C (mean, 113 vs. 59 vs. 84 days; Table 1). 
PGD score grade 3 (n=14), which was assessed at the 
time period between 48 and 72 hours after transplant, 
was more frequently observed in Group B (21.4%) and in 
Group C (22.2%) when compared with that in Group A 
(9.3%), without a statistical significance (Table 2). On the 
other hand, 13 of 14 patients (92.9%) with PGD score 
grade 3 had intraoperative ECMO extension, while 45.2% 
of the remaining non-PGD-grade 3 patients (42/93) 
required ECMO extension (P=0.001; data not shown). 
With regard to early post-LTx outcomes, when compared 
with Groups B or C, patients in Group A had a significantly 
shorter duration of intraoperative ECMO extension (mean, 
2.8 vs. 4.3 vs. 4.5 days; P=0.005), shorter intensive care unit 
(ICU) length of stay (LOS; mean, 13.4 vs. 44.6 vs. 52.1 days; 
P<0.0001), and shorter hospital LOS (mean, 59.6 vs. 79.3 
vs. 80.9; P=0.003). 
After a median of 17.7 months (range, 3.1–40.9 months) 
for survivors, the one year OS rates after LTx according 
to the three groups were 76.3%±5.2% for Group A, 
59.9%±14.3% for Group B, and 14.0%±9.0% for Group C 
(P<0.0001; Figure 2B). Mortality rates at 1, 3, and 6 months 
after LTx were significantly higher in Group C (Table 2). 
The characteristics of each patient in Group C who received 
re-implantation of secondary ECMO are summarized in 
Table 3. The most common cause of second ECMO was 
acute respiratory failure (n=12; 67%), and the mean 
number of days from LTx to implantation of the second 
ECMO was 7.9±5.3 days. Successful weaning from the 
second ECMO was observed in nine patients; however, 
five of these patients did not survive (Table 3). The time 
from LTx to secondary ECMO was longer for the patients 
with weaning failure when compared with those who were 
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Figure 2 Kaplan-Meiers OS curves according to the perioperative uses of ECMO. (A) OS arbitrary divided into 5 clinical situations: blue 
line indicates patients receiving only intraoperative ECMO, green line for patients with intraoperative ECMO extension but without 
bridging nor secondary ECMO, yellow line for those receiving bridging ECMO but without secondary ECMO, red line for patients 
requiring secondary ECMO but not having received bridging ECMO, and black line indicates patients receiving both bridging and 
secondary ECMO; (B) OS arbitrary divided in to 3 clinical situations: Group A (dotted line), merging of the two subgroups indicated by 
blue and green lines; Group B (dashed line), patients indicated by yellow line; Group C (solid line), merging of the two subgroups indicated 
by red and black lines. OS, overall survival; ECMO, extracorporeal membrane oxygenation.
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Table 1 Baseline demographics
Characteristics Group A Group B Group C
No. of patients 75 14 18
Age, years, median [IQR] 55 [45–62] 54 [46–59] 59 [48–63] 
Male, n [%] 41 [55] 8 [57] 15 [83]
Body mass index (kg/m2), median (IQR) 19.7 (18.2–23.3) 20.5 (14.8–23.8) 23.3 (19.5–25.2)
Smoking history, n [%] 37 [49] 6 [43] 13 [72]
LTx indication, n [%]
IPF 44 [59] 6 [43] 12 [67]
BO after allogeneic SCT 9 [12] 2 [14] 1 [5.5]
CVD-related ILD 7 [9] 1 [7] 1 [5.5]
COPD 5 [7] 0 1 [5.5]
Bronchiectasis 5 [7] 0 0
AIP 0 2 [14] 2 [11]
PHT 2 [2] 0 1 [5.5]
LAM 3 [4] 0 0
Others* 0 3 [22] 0
Donor variable
Age, years, median [IQR] 46 [32–51] 35 [24–55] 46 [40–50] 
Male, n [%] 44 [59] 9 [64] 15 [83]
Body mass index (kg/m2), median [IQR] 22.5 (20.5–24.8) 23.8 (21.4–25.3) 22.4 (20.0–24.0)
Smoking history, n [%] 32 [43] 8 [57] 10 [56]
Pre-operative ventilation, days, median [IQR] 142 [74–183] 186 [129–229] 125 [63–211] 
PaO2 (100% FiO2, mmHg) , median [IQR] 467 [387–513] 407 [333–469] 423 [351–475]
Bridging ECMO (n=21) – 14 7 
VA, n [%] – 2 [14] 1 [14]
VV, n [%] – 12 [86] 6 [86]
Waiting time (days), mean ± standard deviation 113±145 59±74 84±114
*, hypersensitive pneumonitis (n=1); bronchiolitis obliterans organizing pneumonia (n=1); ventilator-induced lung injury (n=1). AIP, acute 
interstitial pneumonia; BO, bronchiolitis obliterans; COPD, chronic obstructive lung disease; CVD-ILD, collagen vascular disease related 
interstitial lung disease; ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; IPF, idiopathic pulmonary 
fibrosis; IQR, interquartile range; LAM, lymphangioleiomyomatosis; LTx, lung transplantation; PaO2, partial pressure of arterial oxygen; 
PHT, pulmonary hypertension; SCT, stem cell transplantation; VA, veno-arterial; VV, veno-venous.
successfully weaned (57.0±44.8 vs. 30.0±35.8; P=0.101). 
Causes of mortality are summarized in Table S1. In our 
cohort, infection was the most common cause of death: 
Group A, n=12 of 19 deaths (63%); Group B, n=3 of 
6 deaths (50%); and Group C, n=11 of 14 deaths (79%), and 
the most common pathogen were Acinetobacter baumannii 
(n=11), followed by Pseudomonas aeruginosa (n=6) and 
Klebsiella pneumonia (n=5; Table S1). The ICU LOS and 
hospital LOS were significantly longer for the 27 patients 
with infection-related deaths, when compared with that 
of the other patients (n=81; mean for ICU LOS, 52.6 vs. 
14.8 days, P<0.0001; mean for hospital LOS, 96.5 vs. 
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55.9 days, P<0.0001). 
Clinical characteristics and transplant outcomes of patients 
with pretransplant bridging ECMO
Regarding 21 patients with preoperative bridging ECMO 
(all 14 patients in Group B and 7 patients of Group C), 
the type of ECMO was VA-ECMO in 2 patients and VV 
ECMO in the remaining 19 patients. The mean duration of 
preoperative ECMO bridging was 16.4±15.6 (IQR, 5.5–19.5), 
whereas the mean waiting time was significantly shorter 
for patients with bridging ECMO (63.2±95.4 days; IQR 
7.0–78.5), compared with those without bridging ECMO 
(110.1±140.3 days; IQR 23.3–142.3; P=0.022). The most 
common indication of LTx in the 21 patients with bridging 
ECMO was IPF (n=9, 42.9%), followed by AIP (n=4, 
19.0%). ECMO support was extended postoperatively in all 
but one patient with bridging ECMO, whereas PGD grade 
3 was observed more frequently in patients with bridging 
ECMO when compared with the others (28.6% vs. 9.3%; 
P=0.030). The mean ICU LOS and hospital LOS for the 
pretransplant ECMO group were significantly longer than 
for the other patients (mean for ICU LOS, 57.7±56.1 vs. 
15.7±18.6 days, P<0.0001; mean for hospital LOS, 86.6±48.7 
vs. 60.7±51.6 days, P=0.002). While the OS at 1 year was 
38.9%±11.4% for all 21 patients with pretransplant ECMO, 
there was a significant difference in OS for patients without 
requiring (Group B, n=14; 60.0%±14.3%) versus those with 
(7 of 18 patients in Group C; all died within a year after LTx) 
secondary ECMO support (P=0.003; Figure 2A).
Discussion
Recently, increasing experience of ECMO has been gained 
in terms of pre-, intra-, and postoperative cardiopulmonary 
support for patients undergoing LTx, with favorable 
results. Regarding intraoperative ECMO during LTx, 
Ius et al. demonstrated lower blood product transfusion 
Table 2 Intra- and post-operative data
Characteristics Group A Group B Group C P value
No. of patients 75 14 18
Transplant type, n (%) 0.141
Double 70 (93.3) 14 (100.0) 15 (83.3)
Single 5 (6.7) – 3 (17.7)
Ischemic time (minute), mean ± standard deviation
Right 246±88 257±66 221±71 0.344
Left 329±83 341±78 305±67 0.629
Single 201±88 N/A 204±14 1.000
PGD score grade 2–3, n [%] 30 (40.0) 7 (50.0) 8 (44.0) 0.765
PGD score grade 3, n [%] 7 (9.3) 3 (21.4) 4 (22.2) 0.237
ECMO extension into postoperative care, n (%) 28 (37.3) 13 (92.9) 14 (77.8) <0.001
Duration of ECMO extension 2.8±3.5 4.3±4.7 4.5±3.8 0.005
Mortality, n [%]
1 month 0 2 (14.3) 2 (11.1) 0.006
3 months 2 (2.7) 3 (21.4) 9 (50.0) <0.0001
6 months 14 (18.7) 4 (28.6) 14 (77.8) <0.0001
1 year 16 (21.3) 5 (35.7) 14 (77.8) <0.0001
ICU LOS (days), mean ± standard deviation 13.4±10.6 44.6±56.4 52.1±50.7 <0.0001
Hospital LOS (days), mean ± standard deviation 59.6±53.4 79.3±53.1 80.9±40.5 0.003
ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; LOS, length of stay; PGD, poor graft dysfunction.
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requirements and improved survival in the ECMO group, 
when compared with the CPB group (8); whereas Aigner 
et al. suggested that the versatility of ECMO allows 
maintaining ECMO utilized intraoperatively can be 
extended in the postoperative period (5). However, data 
regarding the optimal approach of ECMO support in the 
postoperative period of LTx remain limited, heterogeneous 
in the setting of its use, and with varying success in results 
(13-16). Following the routine use of intraoperative VA-
ECMO in our institution (10), this present study examined 
our single-center experience of transplant outcomes in 
107 patients undergoing an LTx with the use of ECMO 
support in the perioperative period as a bridge to transplant, 
as an intraoperative cardiopulmonary support, and/or as a 
postoperative bridge to recovery. 
Postoperative extended ECMO support was not used 
electively in any of our patients, and one can expect that 
the patients who did not require additional ECMO support 
other than ECMO as intraoperative cardiopulmonary 
support would show the best clinical outcomes. By 
separately considering those with pretransplant ECMO 
support or posttransplant secondary ECMO implantation, 
we demonstrated that the patients with extended use of the 
intraoperative ECMO had similar (P=0.856) survival rates 
compared with the patients with intraoperative ECMO 
only, with respective OS rates at 6-month and 1-year of 
81% vs. 78% and 78% vs. 74%, respectively. Previous 
studies reporting outcomes of post-LTx ECMO support 
have typically dealt with ECMO as a rescue strategy that 
is mainly utilized for early severe PGD. Moreover, before 
intraoperative ECMO was widely accepted, post-LTx 
ECMO support meant that the implantation of ECMO 
devices was required after LTx and that the best time to 
start post-LTx ECMO had to be determined. According to 
the study by Hartwig et al., 28 of 498 (6%) study patients 
undergoing LTx required VV-ECMO implantation for 
severe PGD after transplant, and 96% of these patients 
were successfully weaned with one year OS of 64% (14). 
Initiation of postoperative ECMO was considered 
when mechanical ventilator requirements reached peak 
inspiratory pressures of 35 cm H2O and the fraction of 
inspired oxygen content surpassed 0.60 in their study (14). 
In contrast, Bermudez et al. reported that 67% (n=39) 
of 58 patients who required early (0 to 7 days after lung 
or heart-lung transplant) ECMO support after LTx for 
PGD were successfully weaned with one year OS of 59%. 
In their cohort, ECMO was usually initiated when PaO2 
was <60 mmHg with a FiO2 >80% (13). While there is 
a possibility that earlier institution of post-LTx ECMO 
support could favorably affect LTx not using intraoperative 
ECMO, recent reports showed that the prevalence of PGD 
and the need for secondary ECMO implantation could 
be reduced by continuing intraoperative ECMO support 
postoperatively (8,17). In our study, 53 of 55 patients 
(96%) were successfully weaned from the extended use 
of intraoperative ECMO support, although 14 of these 
patients (26%) eventually required a secondary ECMO 
after a mean of 32±39 days (IQR 3–55; data not shown). 
On the other hand, the clinical outcomes of secondary 
use of postoperative ECMO support were significantly 
worse than the other subgroups of patients in our study. 
The main indication of secondary ECMO implantation 
after LTx in our cohort was pneumonia or sepsis, which 
is in agreement with a recent study by Marasco et al. (16). 
In their cohort, the indications for early ECMO (<7 days 
posttransplant) were primary graft failure, whereas the 
postoperative ECMO later than 7 days after LTx were 
established for infection and non-specific graft failure (16). 
Additionally, as suggested in the study by Harwig et al. in 
which blood stream infections appeared to be the main 
source of morbidity and mortality in patients with LTx, not 
using intraoperative ECMO, who required posttransplant 
ECMO support, the main causes of death was infection in 
our cohort (14). Mason et al. also identified that the only risk 
factor of mortality in their 22 patients who required post-LTx 
implantation of ECMO was the establishment of ECMO 
for sepsis or pneumonia (18). Moreover, multidrug-resistant 
organisms, including Pseudomonas aeruginosa, Acinetobacter 
baumannii, and extended-spectrum β-lactamase (ESBL)—
producing or carbapenemase-producing Enterobacteriaceae 
(such as Klebsiella pneumoniae), were the main sources of sepsis 
or pneumonia in our study. It is not surprising that hospital-
acquired infections in the ICU would be a significant obstacle 
for patients requiring a second ECMO implantation (19). 
Alternatively, Marasco et al. suggested that the innate disease 
processes determine the poor results seen for late secondary 
ECMO after LTx (16). 
Waiting time before LTx is an important risk factor for 
transplant outcomes in patients awaiting LTx, particularly 
in cases at high risk of acute clinical decompensation that 
inevitably require prolonged mechanical ventilation prior 
to LTx (20,21). Owing to technical advancements (3) and 
promising results from the adoption of “awake ECMO” 
(22,23), pretransplant bridging ECMO for patients 
waiting for an available donor lung is now no longer an 
independent risk factor for mortality, although current 
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recommendations regarding its indication are still based on 
institutional experience (3). Moreover, the implementation 
of the Lung Allocation Score led to improvement in waiting 
list mortality rates (24) and has given priority to patients 
undergoing pretransplant bridging ECMO because of their 
higher scores. In our cohort, ~20% of the patients were 
on ECMO preoperatively, suggesting the severity of these 
high-risk patients. In line with previous reports, our patients 
with bridging ECMO had significantly higher rates of PGD 
grade 3 (29% vs. 9%) and longer mean ICU (58 vs. 16 days) 
and hospital LOS (87 vs. 61 days). While the one year OS 
in all 21 patients with pretransplant bridging ECMO was 
relatively lower (~40%) than other recent reports (25), 
those who did not require a secondary ECMO showed an 
OS reaching 60%. 
Limitations of this study include the retrospective 
nature of the analyses with a single center data and the 
unavailability of the data regarding parameters reflecting 
transplanted lung function. Moreover, decisions on the 
extension of intraoperative ECMO or the initiation of 
secondary ECMO were made on an individual basis, thus 
lacked predetermined criteria. 
In conclusion, our data showed that the postoperative 
extended use of intraoperative ECMO during LTx is 
feasible and provides favorable survival outcomes similar 
to uncomplicated LTx with intraoperative ECMO only. 
However, poor survival outcomes shown for patients who 
required a secondary ECMO indicate that development of 
a solid strategy to reduce the need for secondary ECMO 
implantation after LTx seems important. 
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Table S1 Causes of death
Characteristics Group A Group B Group C
No. of patients 75 14 18
No. of deaths (%) 19 (25%) 6 (43%) 14 (78%)
Causes of death
Infection 12 3 10
Sepsis (Acinetobacter baumanii) 2 – 3
Sepsis (Acinetobacter baumanii, Klebsiella pneumoniae) – – 2
Sepsis (Klebsiella pneumoniae) 1 – –
Sepsis (Klebsiella pneumoniae, Candida glabrata) 1 – –
Sepsis (Vancomycin-resistant enterococcus, Candida albicans) – 1 –
Sepsis (Pseudomonas aeruginosa) – 2 –
Sepsis (unknown pathogen) 1 – –
Pneumonia (Acinetobacter baumanii) 1 – 1
Pneumonia (Acinetobacter baumanii, Klebsiella pneumoniae) 1 – –
Pneumonia (Acinetobacter baumanii, Pseudomonas aeruginosa) – – 1
Pneumonia (Pseudomonas aeruginosa) 2 – –
Pneumonia (Pseudomonas aeruginosa, vancomycin-resistant enterococcus) – – 1
Pneumonia (Burkholderia cepacia, methicillin-resistant Staphylococcus aureus) – – 1
Invasive pulmonary aspergillosis 1 – –
Pneumonia (unknown pathogen) 2 – 1
Hemorrhage 1 – 3
Arrhythmia/cardiogenic shock 1 1 –
Thrombus 1 – –
Thrombotic thrombocytopenic purpura 1 – –
Myocarditis 1 – –
Hepatic failure 1 – –
Bowel perforation – – 1
Hemophagocytic lymphohistiocytosis 1 – –
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